Clinical trial transparency in the pharmaceutical industry is continually evolving, and to stay on top of the news, TrialAssure brings a bi-weekly round-up of some of the key stories. Select recent and relevant stories are as follows:
EMA urged to release full clinical trial data upon authorizing COVID-19 treatments– STAT News
In a recent letter from the independent watchdog group Cochrane, four country directors along with the German Institute for Quality and Efficacy in Health Care urged the European Medicines Agency (EMA) to publish all clinical trial data on the same day a product is authorized for use against COVID-19. The watchdog group and regulators argue that clinical trial transparency can provide confidence in the safety and effectiveness of treatments.
Read the article by Ed Silverman
The WHO International Clinical Trials Registry Platform: providing global clinical trial information to all–BioMed Central Blog
Ghassan Karam and Anna Laura Ross of the World Health Organization (WHO) explain the role of the WHO International Clinical Trials Registry Platform (ICTRP). The experts discuss how freely accessible clinical trial data helps identify gaps and address specific needs in clinical research.
View the blog by Ghassan Karam and Anna Laura Ross
German universities report record number of clinical trial results—TranspariMED
In a December 2019 report, TranspariMED and BUKO Pharma-Kampagne released a report that showed the low levels of clinical data disclosure among German universities. Since the report’s publication—and subsequent media coverage—TranspariMED now reports that German universities have uploaded twice the amount of clinical trials over the past six months than during the preceding six years combined.
Till Bruckner has the full story